Overview
Mercury Bio, an intracellular immunotherapeutics biotechnology company based in Santa Fe, New Mexico, is developing precision medicines designed to treat disease at its biological origin — inside the cell.
The company is focused on developing therapies for diseases driven by intracellular pathology, with the initial therapeutic focus on neurodegenerative diseases including Parkinson’s and Alzheimer’s diseases.
Mercury Bio’s patented MB -TIP™ (Targeting Intracellular Pathologies) combines targeted intracellular access, precision targeting, and engineered immunotherapeutics to enable treatment of diseases driven by intracellular pathology.
Mercury Bio is advancing intracellular immunotherapeutics designed to enable therapeutic engagement of disease biology inside cells, where many diseases originate and progress.